In response to the clots, the U.S. Paused J&J COVID-19 Vaccinations.
U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson’s COVID-19 vaccine after six women under 50 given the shot developed rare blood clots, dealing a fresh setback to efforts to tackle the pandemic.
Following the news, Johnson & Johnson (J&J) said it was delaying the rollout of the vaccine to Europe, a week after regulators there said they were reviewing rare blood clots in four recipients of the shot in the United States.
“Even if causally linked to the vaccine: 6 cases with about 7 million doses (lower than the risk of clots with oral contraceptives) is not something to panic about,” Dr. Amesh Adalja, an infectious disease expert at the Johns Hopkins Center for Health Security in Baltimore, said in an email.
“People are asking me if they should cancel their J&J vaccine appointments and I have told them not to but I know many will and this will stall progress in controlling the pandemic.”
6 Clots in 7 million Doses is less than 1 in a million.
In percentage terms, it is 0.000086%. That is less than the rate of clotting from oral contraceptives.
And we do not even know if these are simply random clotting issues or related to the vaccine.
In short, this is an exceptional over-reaction by US and EU health agencies who halted the AstraZeneca vaccine over similar issues.